Shuo Zheng Selected Research

Leukocyte Elastase (Neutrophil Elastase)

1/2022	Neutrophil Elastase Triggers the Release of Macrophage Extracellular Traps: Relevance to Cystic Fibrosis.
1/2021	Polysulfated Hyaluronan GlycoMira-1111 Inhibits Elastase and Improves Rheology in Cystic Fibrosis Sputum.
1/2020	Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.
10/2018	Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis.
1/2018	Neutrophil elastase increases airway ceramide levels via upregulation of serine palmitoyltransferase.
1/2018	Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum.
4/2014	2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation.
3/2013	Increased expression of senescence markers in cystic fibrosis airways.
1/2008	Proteases and cystic fibrosis.
9/2007	Neutrophil elastase inhibition of cell cycle progression in airway epithelial cells in vitro is mediated by p27kip1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shuo Zheng Research Topics

Disease

13	Cystic Fibrosis (Mucoviscidosis) 01/2022 - 08/2004
12	Hypertension (High Blood Pressure) 01/2022 - 11/2013
12	Inflammation (Inflammations) 01/2022 - 12/2002
8	Lung Diseases (Lung Disease) 01/2021 - 06/2005
4	Virus Diseases (Viral Diseases) 09/2006 - 05/2003
3	Neoplasms (Cancer) 01/2021 - 06/2005
3	Pneumonia (Pneumonitis) 11/2018 - 02/2013
2	Obesity 01/2020 - 10/2016
2	Infections 01/2017 - 09/2006
2	Respiratory Hypersensitivity 02/2013 - 07/2009
2	Postoperative Pain 02/2012 - 10/2011
2	Fever (Fevers) 10/2011 - 12/2010
1	Kidney Diseases (Kidney Disease) 01/2022
1	Vascular Remodeling 12/2021
1	COVID-19 11/2021
1	Communicable Diseases (Infectious Diseases) 11/2021
1	Lymphatic Metastasis 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Triple Negative Breast Neoplasms 01/2021
1	Rhinosinusitis 01/2020
1	Asthma (Bronchial Asthma) 01/2020
1	Cataract (Cataracts) 01/2020
1	Corneal Diseases (Corneal Disease) 01/2020
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2020
1	Genomic Instability 01/2020
1	Acute Lung Injury 01/2020
1	Empyema 11/2018
1	Stroke (Strokes) 01/2018
1	Metabolic Diseases (Metabolic Disease) 10/2016
1	Diabetes Mellitus 10/2016
1	Hemorrhage 04/2014
1	Hematuria 02/2012
1	Dysuria 02/2012
1	Pain (Aches) 02/2012

Drug/Important Bio-Agent (IBA)

10	Leukocyte Elastase (Neutrophil Elastase)IBA 01/2022 - 09/2007
8	SodiumIBA 01/2022 - 11/2013
5	Antiviral Agents (Antivirals)IBA 11/2021 - 05/2003
4	CytokinesIBA 11/2021 - 05/2003
4	Peptide Hydrolases (Proteases)FDA Link 01/2020 - 01/2008
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2006 - 12/2002
3	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2021
3	Dopamine Receptors (Dopamine Receptor)IBA 01/2022 - 11/2013
3	Particulate MatterIBA 11/2021 - 01/2018
3	Heparin (Liquaemin)FDA LinkGeneric 01/2020 - 04/2014
2	G-Protein-Coupled Receptor Kinase 4IBA 01/2022 - 10/2021
2	Circular RNAIBA 12/2021 - 01/2021
2	Hyaluronic Acid (Hyaluronan)IBA 01/2021 - 01/2020
2	Pancreatic Elastase (Elastase)IBA 01/2021 - 01/2020
2	AnticoagulantsIBA 01/2020 - 04/2014
2	Protease Inhibitors (Protease Inhibitor)IBA 10/2018 - 04/2014
2	CeramidesIBA 01/2018 - 01/2018
2	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 01/2018 - 11/2014
2	SphingolipidsIBA 01/2018 - 01/2018
2	ChemokinesIBA 04/2014 - 07/2009
2	OzoneIBA 02/2013 - 07/2009
2	IsoprostanesIBA 02/2013 - 07/2009
1	uroguanylinIBA 01/2022
1	Natriuretic AgentsIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 12/2021
1	Therapeutic UsesIBA 11/2021
1	Antihypertensive Agents (Antihypertensives)IBA 10/2021
1	candesartanIBA 10/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	PolymersIBA 01/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	pyruvate dehydrogenase kinase 4IBA 01/2021
1	GlycosaminoglycansIBA 01/2020
1	AllergensIBA 01/2020
1	Exonucleases (3' 5' Exonuclease)IBA 01/2020
1	Heparitin Sulfate (Heparan Sulfate)IBA 01/2020
1	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 01/2020
1	SmokeIBA 01/2020
1	Sulfates (Sulfates, Inorganic)IBA 01/2020
1	AdiponectinIBA 01/2020
1	AdipokinesIBA 01/2020
1	L 644711 (B-3(+))IBA 11/2018
1	OligosaccharidesIBA 10/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018
1	thermozymocidin (myriocin)IBA 01/2018
1	AntioxidantsIBA 01/2018
1	CurcuminIBA 01/2018
1	G-Protein-Coupled Receptor KinasesIBA 01/2018
1	AlarminsIBA 01/2017
1	HMGB1 Protein (HMG1)IBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Amino Acids FDA Link 10/2016
1	Peptides (Polypeptides)IBA 10/2016
1	Small Interfering RNA (siRNA)IBA 10/2016
1	AngiotensinsIBA 01/2015
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 04/2014
1	Chemotactic FactorsIBA 04/2014
1	renalaseIBA 03/2014
1	GastrinsIBA 11/2013
1	cyclopentenoneIBA 02/2013

Therapy/Procedure

6	Therapeutics 11/2021 - 05/2003
2	Operative Time 10/2011 - 12/2010
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022
1	Contraindications 01/2020
1	Stents 02/2012